Colinz Laboratories Ltd has announced plans to sell two key assets valued at a minimum of Rs 6.00 crores, subject to shareholder approval through a postal ballot. The Board of Directors approved the proposal on October 14, 2025, to dispose of a pharmaceutical manufacturing factory in Sinnar, Nashik, and office premises in Mumbai.

Asset Details and Rationale

The assets slated for sale include:

1. Pharmaceutical Manufacturing Factory:

   • Location: Plot No 60, STICE, Sinnar-Shirdi Road, Sinnar, Nashik-422112
   • Minimum Valuation: Rs 3.00 crores
   • Rationale for Sale:
     • High costs associated with modifying the factory to comply with new WHO norms
     • Deteriorating infrastructure (constructed between 1995-1998)
     • Need for extensive modifications, new machinery, and additional manpower

2. Office Premises:

   • Location: A-101, A-102, A-103 Pratik Estate, Mulund Link Road, Bhandup West, Mumbai-400078
   • Total Area: 1088 sq feet (across three units)
   • Minimum Valuation: Rs 3.00 crores
   • Rationale for Sale:
     • 25-year-old premises lacking basic facilities like elevators and adequate parking
     • Redevelopment constraints due to nearby electric tower installations

Shareholder Approval Process

The company is seeking shareholder approval through a postal ballot with the following key dates:

• E-voting Period: October 15 to November 14, 2025
• Cut-off Date for Shareholder Eligibility: October 7, 2025

Future Plans

Colinz Laboratories is considering alternative options, including:

• Setting up a new factory in Gujarat
• Acquiring a ready-made facility that complies with revised schedule and WHO norms

The company plans to use the proceeds from the asset sales for these potential investments, aiming to construct a new WHO-compliant facility if funds permit.

Legal and Regulatory Compliance

The proposed sales require shareholder approval as special resolutions under Section 180(1)(a) of the Companies Act, 2013. The transactions are considered material events under SEBI regulations, and necessary stock exchange intimations will be made.

Management Commentary

While no direct quotes were provided, the management's decision appears to be driven by the need to upgrade manufacturing capabilities to meet new regulatory standards and improve operational efficiency. The move also aims to address the limitations of aging infrastructure at both the factory and office locations.

Shareholders will play a crucial role in determining the future direction of Colinz Laboratories through their votes on these proposed asset sales. The outcome of the postal ballot will be a significant factor in shaping the company's strategic plans for modernization and compliance with industry standards.

Colinz Laboratories Limited, a prominent player in the pharmaceutical sector, has announced significant corporate decisions following its recent Board of Directors meeting. The company has approved its unaudited financial results for the quarter ended June 30, 2025, and made key appointments to strengthen its leadership team.

Financial Results and Corporate Governance

The Board of Directors convened on July 31, 2025, to review and approve the unaudited financial results for the first quarter of the fiscal year 2025-26. In compliance with SEBI regulations, the company's statutory auditors conducted a limited review of these results. Additionally, the Board approved the Director's Report, Management Discussion Report, Corporate Governance Report, and CEO's certification for the year ended March 31, 2025.

Key Appointments and Reappointments

In a move to bolster its leadership, Colinz Laboratories has made two significant appointments:

1. Mr. Swapnil Jayeshbhai Madiyar (DIN: 08520796) has been recommended for appointment as a Non-Promoter, Non-Executive Director, effective September 30, 2025. Mr. Madiyar brings a wealth of experience across key business verticals, including Technology, HR, Marketing, Operations, and General Management.

2. Mr. N. K. Menon (DIN: 01111297) has been recommended for reappointment as Whole Time Director and CEO for a one-year term from October 1, 2025, to September 30, 2026.

Both appointments are subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Annual General Meeting and Auditor Appointments

The company has scheduled its 39th AGM for September 30, 2025, to be held via video conference. The register of members will remain closed from September 23 to September 30, 2025, for the purpose of the AGM.

In other governance matters, Colinz Laboratories has appointed:

• M/s. Sanjay Dholakia & Associates as the Secretarial Auditor for the financial year 2025-26.
• CA Ajay Ramsevak Sharma (Firm Reg. no. 137003W) as the Internal Auditor for the financial year 2025-26.

E-voting Details

For the upcoming AGM, the company has set September 23, 2025, as the cut-off date for determining eligible shareholders for e-voting. The e-voting period will be open from September 27, 2025 (9:30 A.M. IST) to September 29, 2025 (5:00 P.M. IST).

These developments underscore Colinz Laboratories' commitment to corporate governance and strategic growth as it moves forward in the dynamic pharmaceutical industry.